Acute megakaryoblastic transformation from essential thrombocythemia

Blastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes.

Three patients developed blastic transformation of essential thrombocythemia (tET). Morphological studies in all patients showed that the majority of blasts had either myeloblastic or myelomonoblastic differentiation. Immunologic assays of hematopoietic cells were performed in two patients. In patient 1, 86% of peripheral blood mononuclear cells (predominantly blasts) reacted with a monoclonal ...

Myelomegakaryoblastic transformation of essential thrombocythemia.

Essential thrombocytherrlia, considered one of the least common of the myeloproliferative disorders, is being diag nosed more frequently with the increasing use of automated blood cell counters. Essential thrombocythemia described by Epstein and Goendel in 1934 is a diagnosis of exclusion i.e., exclusion of all sy stemic conditions associated with thrombocytosis in an individual with a persiste...

Essential thrombocythemia and acute myocardial infarction.

Essential thrombocythemia

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The clinical pictu...

Ruxolitinib for essential thrombocythemia?